Signature Mapping TBDx Tuberculosis Diagnostics Solution to Be Deployed in Remote Intensive Case Finding Project

HERNDON, VA–(09/14/11)- Signature Mapping Medical Sciences, Inc. a subsidiary of Applied Visual Sciences, Inc. (OTC.BB: APVS.OBNews) announces today through its ongoing partnership with the Aurum Institute for Health Research in South Africa, Signature Mapping Medical Sciences, Inc. will be deploying the TBDx automated slide management visualization screening solution as a component of an innovative mobile tuberculosis (TB) case finding project. The mobile unit aims to deliver a comprehensive tuberculosis detection and treatment capability to remote villages in South Africa.

The mobile TB case finding project has received approval from a governmental funding agency, with funds available for the acquisition of TBDx, upon approval of the agency’s fiscal year budget. Funding will allow for the creation and deployment of up to 4 mobile units. The units will contain the latest and most sophisticated technologies for the detection of tuberculosis. TBDx will work alongside digital X-rays and GeneXpert, the molecular diagnostic system, as the Aurum Institute seeks to expand effective TB case finding closer to the point of care using the combined technologies.

“Until we can bring effective diagnosis closer to the people most in need, the devastating effects of TB will continue to plague our communities,” noted Dr. Dave Clark, Deputy CEO of the Aurum Institute. “We see these mobile units, outfitted with TBDx and other technologies, playing an innovative role in collecting sputum samples, visualizing slides, screening patients, and assisting in case diagnosis, without extensive deployment of scarce laboratory and radiology staff resources.”

“We could not be more pleased to be participating in this vitally important project with Aurum,” commented Bill Donovan, President and Chief Operating Officer of Signature Mapping Medical Sciences. “Providing innovative, cutting-edge technologies to the poorest and most heavily TB burdened areas of the country will allow more South African citizens to be screened and treated. Mass population screening in those areas could potentially slow the spread of the disease and have a lasting impact on the growth of the disease.”

About TBDx
The SM TBDx solution combines Applied Visual Sciences’ highly sensitive and specific image analysis software with an automated slide loader capable of processing 200 slides without human intervention, a bar code reader, an automated microscope stage navigator to process the slide through the capture of 100 fields of view (FOV), and an auto-focus camera to digitally capture each FOV. SM TBDx Manages and synchronizes the hardware components for hands-free slide acquisition and TB detection analysis. A video of the TBDx automated solution is available at the following link: http://www.youtube.com/watch?v=Wn6k5YxhFjU

About Aurum Institute
The Aurum Institute is an internationally recognized African research and health systems organization, dedicated to making a major impact in the fight against TB and HIV. For more information go to www.auruminstitute.org

About Applied Visual Sciences, Inc.
Applied Visual Sciences, Inc. is the holding company and IT development organization for subsidiaries specializing in high-performance imaging analysis technologies and advanced analytics for automated recognition of targets of interest.

Applied Visual Sciences’ subsidiaries include Guardian Technologies International, Inc., a homeland security/defense technology entity, and Signature Mapping Medical Sciences, Inc., a healthcare technology entity. The company is quoted on the OTC Bulletin Board under the symbol APVS.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995:
Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, capital raising activities, trends in the markets, variations in the company’s cash flow, competition, business development efforts, technology availability and cost of materials and other risk factors. Factors that could cause actual results to differ materially are discussed in the Company’s most recent filings with the Securities and Exchange Commission.

Contact:

For Applied Visual Sciences:
William Donovan
+1 703-464-5495

For Signature Mapping Medical Sciences:
Sean Kennedy
+1 703-464-5495

For Public Relations:
Julie Shepherd of Accentuate PR
+1 815-479-1833

Advertisements
This entry was posted in Corporate, Healthcare, TB and tagged , , , , , , , . Bookmark the permalink.